Case Report: rapid clinical complete response to Iparomlimab and Tuvonralimab combined with radiotherapy and chemotherapy in a patient with MSS/pMMR locally advanced rectal cancer.

Authors

Jue Wang, Tao Yang, Jingrui Zhou, Weimin Chen, Guiwei Wang, Chaoyu Mei, Ziwei Chen, Jibiao Li, Tao Shen

Published in

Frontiers in oncology. Volume 16. Pages 1936564. Epub Sep 15, 2026.

Abstract

To investigate the efficacy and safety of Iparomlimab and Tuvonralimab, a PD-1/CTLA-4 bispecific antibody, in combination with chemoradiotherapy for a patient with microsatellite stable/mismatch repair proficient (MSS/pMMR) locally advanced rectal cancer (LARC), and to analyze the mechanism of achieving short-term clinical complete response (cCR).
This case report presents a 61-year-old male with stage cT3N2aM0 IIIB MSS/pMMR rectal cancer. The patient received neoadjuvant therapy with Iparomlimab and Tuvonralimab (300mg per dose) plus XELOX regimen chemotherapy and radiotherapy (45Gy/25F). Responses were regularly assessed via digital rectal examination, imaging, endoscopy, and pathology.
After treatment, clinical complete response (cCR) was initially evidenced by MRI at week 12 and subsequently confirmed by endoscopic assessment combined with pathologic biopsy at week 20. No grade 3 or higher immune-related adverse events occurred. At the last follow-up in March 2026, no recurrence was observed.
This case suggests that Iparomlimab and Tuvonralimab combined with chemoradiotherapy may induce rapid cCR in MSS/pMMR LARC, offering a promising organ-preserving strategy through immunotherapy. Further large-sample studies are warranted.

PMID:
42812258
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.